EUCTR2020-002986-32-PL进行中（未招募）1 期
A Phase 3b Randomized, Double-Blind, Multi-Center Study toCompare the Safety and Efficacy of Omadacycline IV/PO toMoxifloxacin IV/PO for Treating Adult Subjects withCommunity-Acquired Bacterial Pneumonia (CABP)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 670
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Written and signed informed consent must be obtained before any protocol specific assessment is performed.
- •2.Male or female, aged 18 years or older.
- •3.Has at least 3 of the following symptoms:
- •Production of purulent sputum
- •Dyspnea (shortness of breath)
- •Pleuritic chest pain
- •4.Has at least TWO of the following abnormal vital signs:
- •Fever or hypothermia documented by the investigator (temperature > 38.0°C [100.4°F] or < 36.0°C [95.5°F])
- •Hypotension with SBP < 90 mm Hg
- •Heart rate > 90 beats per minute (bpm)
- •RR > 20 breaths/minute
- •5.Has at least 1 clinical sign or laboratory finding associated with CABP:
- •Hypoxemia (PaO2 < 60 mm Hg by ABG or oxygen saturation < 90% by pulse oximetry)
- •Physical examination findings of pulmonary consolidation (eg, dullness on percussion, bronchial breath sounds, or egophony)
- •An elevated total white blood cell (WBC) count (> 12,000 cells/mm3) or leucopenia (WBC < 4,000 cells/mm3) or elevated immature neutrophils (> 15% band forms) (regardless of total peripheral WBC count)
- •6.Has disease categorized as being PORT Risk Class III or IV at Screening (see PORT Risk Class calculation in Appendix 5).
- •7.Radiographically-confirmed pneumonia, ie, new or progressive pulmonary infiltrate(s) on chest X-ray (CXR) or chest computed tomography (CT) scan consistent with acute bacterial pneumonia within 48 hours prior to the first dose of test article.
- •8.Is expected to require a minimum of at least 2 days of iv therapy for the initial treatment of CABP.
- •9.Females must have a negative pregnancy test at Screening and agree to comply with using an acceptable method of birth control as per your local requirements (eg, abstinence, po contraceptive, intrauterine device [IUD], barrier contraception [condom], tubal ligation, hysterectomy, bilateral oophorectomy, postmenopausal or vasectomized partner) from Screening through PTE. Males must agree to use an acceptable method of birth control with female partner(s) and must not donate sperm from Screening through PTE.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 640
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Has received 1 or more dose(s) of a potentially effective systemic antibacterial treatment within the 72 hours prior to the first dose of IMP(a subject will be considered to have received a potentially effective systemic antibacterial treatment if the pathogen identified as causing infection is shown to be susceptible to the antibacterial given or, in the circumstance where a pathogen is not identified, if the antibacterial agent is approved for treatment of pneumonia or is known to have activity against any of the leading causes of CABP [eg, S. pneumoniae, H. influenzae, M.catarrhalis, S. aureus, L. pneumophila]).
- •2.Is known or suspected to have CABP caused by a pathogen that may be resistant to either test article (eg, P. aeruginosa, Proteus spp., M. morganii, Providencia spp., P. jiroveci, obligate anaerobes, mycobacteria, fungal pathogens).
- •3.Suspected or confirmed empyema or lung abscess.
- •4.Confirmed or suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on local SoC assessments.
- •5.Subjects who reside in a long-term care or subacute/intermediate healthcare facility or a subject with pneumonia following a recent hospitalization.
- •6.Has a known history of having experienced unstable cardiac disease within the 3 months prior to Screening or presents with a tachyarrhythmia (excl sinus tachycardia).
- •7.Has a QT interval corrected for heart rate using Fridericia’s formula (QTcF) > 450 msec (males) or > 470 msec (females), are known to have long QT syndrome, use drugs of potential proarrhythmic or QT prolonging effect.
- •8.Has other contraindications to receiving a systemic fluoroquinolone antibiotic, including confirmed or suspected peripheral neuropathy, tendon disorder, myasthenia gravis, cirrhosis, aortic aneurysm, or central nervous system (CNS) disorder that may predispose to seizures or lower the seizure threshold.
- •9.History or evidence of severe renal disease or has a calculated creatinine clearance (CrCl) of < 30 mL/minute, using the Cockcroft-Gault equation . Requires dialysis (eg, hemodialysis, peritoneal dialysis).
- •10.Significant immunological disease determined by any of the following:
- •Current or anticipated neutropenia defined as < 500 neutrophils/mm3
- •Known infection with HIV and a cluster of differentiation 4 (CD4) count that is unknown or documented to be
- •< 200 cells/mm3 within the last year, or an AIDS-defining illness
- •11.Cancer chemotherapy, radiotherapy, or potent, non-corticosteroid immunosuppressant drugs within the past 3 months, or the receipt of corticosteroids equivalent to or greater than 40 mg of prednisone per day or for more than 14 days in the prior 30 days (. Exception: Systemic corticosteroids added within 24 hours of randomization or after randomization as adjunctive therapy for the current episode of CABP is allowed.
- •12.Requires acute pharmacologic intervention to stabilize BP and/or adequate tissue perfusion OR meets septic shock criteria (ALL):
- •Meets at least 2 criteria for sepsis as defined by the quick Sequential Organ Failure Assessment (qSOFA) score: (a) Altered mental status with Glasgow Coma Scale (GCS) < 15, (b) RR = 22 breaths per minute, and (c) SBP = 100 mmHg
- •Despite adequate fluid resuscitation, persistent hypotension requiring vasopressors
- •to maintain mean MAP = 65 mmHg.
- •Serum lactate = 2 mmol/L
- •13.PORT Risk Class I, II, and V patients.
- •14.Requires or expected to require Intensive Care Unit admittance or invasive or non-invasive ventilation.
研究者
相似试验
进行中（未招募）
1 期
Clinical Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin in patients withCommunity-Acquired Bacterial Pneumonia (CABP)EUCTR2020-002986-32-HUParatek Pharmaceuticals, Inc.670
进行中（未招募）
1 期
Clinical Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin in patients withCommunity-Acquired Bacterial Pneumonia (CABP)EUCTR2020-002986-32-BGParatek Pharmaceuticals, Inc.670
进行中（未招募）
1 期
Clinical Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin Iin patients withCommunity-Acquired Bacterial Pneumonia (CABP)EUCTR2020-002986-32-HRParatek Pharmaceuticals, Inc.670
进行中（未招募）
1 期
A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women with a Previous Singleton Spontaneous Preterm Delivery - NDEUCTR2009-014696-52-ITHOLOGIC, INC.1,707
进行中（未招募）
1 期
An Efficacy and Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS)EUCTR2019-004256-11-ITMitsubishi Tanabe Development America Inc.380